Catalyst Pharma downgraded by ROTH Capital with a new price target
$CPRX
Biotechnology: Pharmaceutical Preparations
Health Care
ROTH Capital downgraded Catalyst Pharma from Buy to Neutral and set a new price target of $15.50 from $10.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | $35.00 | Overweight | Stephens |
| 3/14/2024 | $27.00 | Buy | Citigroup |
| 3/7/2024 | $23.00 | Buy | BofA Securities |
| 12/21/2023 | $30.00 | Outperform | Oppenheimer |
| 8/24/2022 | $10.00 → $15.50 | Buy → Neutral | ROTH Capital |
| 2/8/2022 | $9.00 → $12.00 | Buy | HC Wainwright & Co. |
4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed $100,000 to the American Red Cross to support ongoing relief efforts for communities impacted by Hurricane Helene. "At Catalyst, our commitment to the community is unwavering, particularly in times of crisis," said Richard J. Daly, President and CEO of Catalyst. "We extend our heartfelt sympathies to those affected by Hurricane Helene and are honored to contribute to the
Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted to Executive Vice President, Chief Commercial Officer CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024. Mr. Kalb will report directly to the Company's Chief Executive Officer and will serve as a member of the Company's executive leadership team. Mr. Kalb's distinguished career in
CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Richard J. Daly as its new Chief Executive Officer ("CEO") effective January 1, 2024. Mr. Daly is a seasoned pharmaceutical executive bringing more than three decades of experience to Catalyst. In order to facilitate an orderly transition, Patrick J. McEnany, Founder, Chairman, and CEO, will retire from the CEO position effective December 31, 2023, and at that time will contin
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below. Piper Sandler 36th Annual Healthcare ConferenceDate: Tuesday, December 3, 2024Presentation: 2:00 PM ETWebcast Link Citi's 2024 Global Healthcare Conference Date: Wednesday, December 4, 2024Prese
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named on the BioSpace 2025 Best Places to Work. Catalyst is among 50 U.S. operating employers on the Best Places to Work list. The recipients are recognized as the most sought-after in the industry by the life sciences community. "We are honored to be recognized by BioSpace as one of the Best Places to Work in 2025," said Richard J. Daly, President and Ch
Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance Highlights Operational Excellence and Strong Commercial Execution FIRDAPSE® Q3 2024 Net Product Revenues of $79.3 Million, Representing a 19.7% YoY Increase AGAMREE® Q3 2024 Net Product Revenues of $15.0 Million, Demonstrating Early U.S. Launch Success FYCOMPA® Q3 2024 Net Product Revenues of $32.1 Million Q3 2024 GAAP Net Income of $43.9 Million, $0.35 Per Share Diluted Q3 2024 Non-GAAP Net Income of $71.1 Million, $0.57 Per Share Diluted Updating 2024 Full Year Total Revenue Guidance to Be
144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
Catalyst Pharmaceuticals (NASDAQ:CPRX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 3 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $28.43, along with a high estimate of $34.00 and a low estimate of $23.00. Marking an in
HC Wainwright & Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and maintains $26 price target.
Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00
Citigroup initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $27.00
BofA Securities initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $23.00
SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance Highlights Operational Excellence and Strong Commercial Execution FIRDAPSE® Q3 2024 Net Product Revenues of $79.3 Million, Representing a 19.7% YoY Increase AGAMREE® Q3 2024 Net Product Revenues of $15.0 Million, Demonstrating Early U.S. Launch Success FYCOMPA® Q3 2024 Net Product Revenues of $32.1 Million Q3 2024 GAAP Net Income of $43.9 Million, $0.35 Per Share Diluted Q3 2024 Non-GAAP Net Income of $71.1 Million, $0.57 Per Share Diluted Updating 2024 Full Year Total Revenue Guidance to Be
CORAL GABLES, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2024 financial results after the market close on Wednesday, November 6, 2024. Catalyst's management team will host a conference call and webcast on Thursday, November 7, 2024, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast Details Date:November 7, 2024Time:8:30 AM ET
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from contracts with customers of CHF 14.1 million (H1-2023: CHF 3.9 million)Operating result of CHF -17.7 million (H1-2023: CHF -20.3 million) and net result of CHF -15.3 million (H1-2023: CHF -23.3 million)AGAMREE® (vamorolone) launched in Germany and Austria as first European markets; North America partner has launched in the U.S.Approval of AGAMREE in the UK for the treatment of Duchenne muscular dystrophy (DMD); new drug application (NDA) in DMD under regulatory priority review in China Cash and cash